Cargando…
Evaluation of the In Vitro and In Vivo Antifungal Activity of APX001A/APX001 Against Candida auris
BACKGROUND: Candida auris, an emerging multidrug-resistant yeast, causes deadly invasive infections with high mortality. C. auris strains often show high MICs to fluconazole and amphotericin B, and some are resistant to all 3 major antifungal classes, limiting treatment options. We tested 16 C. auri...
Autores principales: | Larkin, Emily, Long, Lisa, Hager, Christopher, Shaw, Karen Joy, Ghannoum, Mahmoud |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630936/ http://dx.doi.org/10.1093/ofid/ofx163.1206 |
Ejemplares similares
-
In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
por: Hager, Christopher L., et al.
Publicado: (2018) -
In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
por: Shaw, Karen Joy, et al.
Publicado: (2018) -
Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis
por: Wiederhold, Nathan P., et al.
Publicado: (2019) -
Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species
por: Kapoor, Mili, et al.
Publicado: (2019) -
Fungal Cytological Profiling of Candida albicans Exposed to Diverse Antifungal Agents Including the Novel Gwt1 inhibitor APX001A
por: Sharp, Marc, et al.
Publicado: (2017)